Karin Mattsson
Plus aucun poste en cours
Profil
Karin Mattsson worked as Director of Research & Development at Biovica International AB from 2017 to 2020.
Prior to that, she worked as a Project Manager at Biovator AB and as Deputy Head of Research & Development at CareDx AB.
She holds a doctorate degree from Karolinska Institutet and a graduate degree from the University of Uppsala.
Anciens postes connus de Karin Mattsson
Sociétés | Poste | Fin |
---|---|---|
BIOVICA INTERNATIONAL AB | Directeur Technique/Scientifique/R&D | 01/01/2020 |
Biovator AB
Biovator AB Miscellaneous Commercial ServicesCommercial Services Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009. | Corporate Officer/Principal | 13/03/2012 |
CareDx AB
CareDx AB Medical SpecialtiesHealth Technology CareDx AB develops reagents and kits for low and high resolution human leukocyte antigen typing. Its products include Olerup SSP, Olerup QTYPE, Olerup XM-ONE, Olerup SBT and Olerup Gamma-Type. The comaony was founded by Olle Olerup in 1992 and is headquartered in Saltsjobaden, Sweden. | Corporate Officer/Principal | - |
Formation de Karin Mattsson
Karolinska Institutet | Doctorate Degree |
University of Uppsala | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BIOVICA INTERNATIONAL AB | Health Technology |
Entreprise privées | 2 |
---|---|
Biovator AB
Biovator AB Miscellaneous Commercial ServicesCommercial Services Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009. | Commercial Services |
CareDx AB
CareDx AB Medical SpecialtiesHealth Technology CareDx AB develops reagents and kits for low and high resolution human leukocyte antigen typing. Its products include Olerup SSP, Olerup QTYPE, Olerup XM-ONE, Olerup SBT and Olerup Gamma-Type. The comaony was founded by Olle Olerup in 1992 and is headquartered in Saltsjobaden, Sweden. | Health Technology |